Ignite Creation Date:
2024-05-05 @ 5:06 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00385125
Status:
UNKNOWN
Last Update Posted:
2006-10-06
First Post:
2006-10-05
Brief Title:
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Sponsor:
University of Magdeburg
Organization:
University of Magdeburg
Study Overview
Official Title:
Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment Who Received or Did Not Qualify for Autologous Stem Cell Transplantation
Status:
UNKNOWN
Status Verified Date:
2006-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment who received or did not qualify for autologous stem cell transplantation
Detailed Description:
Phase II study for treatment of patients with relapsed or primary refractory aggressive B- cell NHL and anthracycline chemotherapy pretreatment who received or did not qualify for autologous stem cell transplantation Aim is to find response rates and duration of combination chemotherapy bendamustinerituximab in patients with relapsed or refractory CD 20 positive B cell NHL
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None